Переходьте в офлайн за допомогою програми Player FM !
Cutting-Edge Concepts in HIV Care: Long-Acting Therapies
Manage episode 347018397 series 2884624
In this episode, Paul E. Sax, MD, discusses long-acting (LA) injectables for HIV treatment, including:
- Guidance on the use of LA cabotegravir (CAB) + rilpivirine (RPV)
- Risk factors for virologic failure of LA CAB + RPV
- The ATLAS-2M study
- Combined clinical trials of LA CAB + RPV
- Practical considerations for LA CAB + RPV
- Implementation of LA CAB + RPV
- Switching to LA CAB + RPV without an oral lead-in, including a discussion of the FLAIR extension study
- Supporting candidates for LA antiretroviral therapy (ART)
- Discussion of an implementation study of LA CAB + RPV in patients with challenges to oral ART adherence in San Francisco
- Future LA ART
- The investigational LA HIV capsid inhibitor lenacapavir (LEN)
- LEN resistance from the CAPELLA and CALIBRATE studies
- LEN injection-site reactions in the CAPELLA and CALIBRATE studies
Presenter:
Paul E. Sax, MD
Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Link to full program:
https://bit.ly/3VIsDTg
Follow along with the slides at:
http://bit.ly/3Gh9AKG
379 епізодів
Manage episode 347018397 series 2884624
In this episode, Paul E. Sax, MD, discusses long-acting (LA) injectables for HIV treatment, including:
- Guidance on the use of LA cabotegravir (CAB) + rilpivirine (RPV)
- Risk factors for virologic failure of LA CAB + RPV
- The ATLAS-2M study
- Combined clinical trials of LA CAB + RPV
- Practical considerations for LA CAB + RPV
- Implementation of LA CAB + RPV
- Switching to LA CAB + RPV without an oral lead-in, including a discussion of the FLAIR extension study
- Supporting candidates for LA antiretroviral therapy (ART)
- Discussion of an implementation study of LA CAB + RPV in patients with challenges to oral ART adherence in San Francisco
- Future LA ART
- The investigational LA HIV capsid inhibitor lenacapavir (LEN)
- LEN resistance from the CAPELLA and CALIBRATE studies
- LEN injection-site reactions in the CAPELLA and CALIBRATE studies
Presenter:
Paul E. Sax, MD
Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Link to full program:
https://bit.ly/3VIsDTg
Follow along with the slides at:
http://bit.ly/3Gh9AKG
379 епізодів
すべてのエピソード
×Ласкаво просимо до Player FM!
Player FM сканує Інтернет для отримання високоякісних подкастів, щоб ви могли насолоджуватися ними зараз. Це найкращий додаток для подкастів, який працює на Android, iPhone і веб-сторінці. Реєстрація для синхронізації підписок між пристроями.